A clinical protocol for a German birth cohort study of the Maturation of Immunity Against respiratory viral Infections (MIAI).


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 05 06 2024
accepted: 29 08 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: epublish

Résumé

Respiratory viral infections (RVIs) are a major global contributor to morbidity and mortality. The susceptibility and outcome of RVIs are strongly age-dependent and show considerable inter-population differences, pointing to genetically and/or environmentally driven developmental variability. The factors determining the age-dependency and shaping the age-related changes of human anti-RVI immunity after birth are still elusive. We are conducting a prospective birth cohort study aiming at identifying endogenous and environmental factors associated with the susceptibility to RVIs and their impact on cellular and humoral immune responses against the influenza A virus (IAV), respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The MIAI birth cohort enrolls healthy, full-term neonates born at the University Hospital Würzburg, Germany, with follow-up at four defined time-points during the first year of life. At each study visit, clinical metadata including diet, lifestyle, sociodemographic information, and physical examinations, are collected along with extensive biomaterial sampling. Biomaterials are used to generate comprehensive, integrated multi-omics datasets including transcriptomic, epigenomic, proteomic, metabolomic and microbiomic methods. The results are expected to capture a holistic picture of the variability of immune trajectories with a focus on cellular and humoral key players involved in the defense of RVIs and the impact of host and environmental factors thereon. Thereby, MIAI aims at providing insights that allow unraveling molecular mechanisms that can be targeted to promote the development of competent anti-RVI immunity in early life and prevent severe RVIs. https://drks.de/search/de/trial/, identifier DRKS00034278.

Identifiants

pubmed: 39355253
doi: 10.3389/fimmu.2024.1443665
pmc: PMC11442434
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1443665

Informations de copyright

Copyright © 2024 Hartmann, Khan, Schöning, Richter, Willers, Pirr, Heckmann, Dirks, Morbach, Konrad, Fries, Winkler, Büchel, Seidenspinner, Fischer, Vollmuth, Meinhardt, Marissen, Schmolke, Haid, Pietschmann, Backes, Dölken, Löber, Keil, Heuschmann, Wöckel, Sagar, Ulas, Forslund-Startceva, Härtel and Viemann.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Carina R Hartmann (CR)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Robin Khan (R)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Jennifer Schöning (J)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Maximilian Richter (M)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Maike Willers (M)

Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.

Sabine Pirr (S)

Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.

Julia Heckmann (J)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Johannes Dirks (J)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
German Center for Infection Research, Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

Henner Morbach (H)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
Center for Primary Immunodeficiencies and Autoinflammatory Diseases (CIDA), University Hospital Würzburg, Würzburg, Germany.

Monika Konrad (M)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Elena Fries (E)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Magdalene Winkler (M)

Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.

Johanna Büchel (J)

Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.

Silvia Seidenspinner (S)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Jonas Fischer (J)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Claudia Vollmuth (C)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Martin Meinhardt (M)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Janina Marissen (J)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Mirco Schmolke (M)

Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Sibylle Haid (S)

Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research (TWINCORE), a joint venture between the Helmholtz Centre for Infection Research and The Hannover Medical School, Hannover, Germany.

Thomas Pietschmann (T)

Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research (TWINCORE), a joint venture between the Helmholtz Centre for Infection Research and The Hannover Medical School, Hannover, Germany.
German Centre for Infection Research, Partner Site Braunschweig-Hannover, Braunschweig, Germany.

Simone Backes (S)

Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.

Lars Dölken (L)

Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
Institute of Virology, Hannover Medical School, Hannover, Germany.

Ulrike Löber (U)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Experimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany.

Thomas Keil (T)

Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
State Institute of Health I, Bavarian Health and Food Safety Authority, Erlangen, Germany.

Peter U Heuschmann (PU)

Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany.
Clinical Trial Centre Würzburg, University Hospital Würzburg, Würzburg, Germany.

Achim Wöckel (A)

Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.
Department of Medicine II (Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases), Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.

Thomas Ulas (T)

Systems Medicine, German Center for Neurodegenerative Diseases Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
PRECISE Platform for Single Cell Genomics and Epigenomics, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) and University of Bonn, Bonn, Germany.
Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.

Sofia K Forslund-Startceva (SK)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Experimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

Christoph Härtel (C)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.

Dorothee Viemann (D)

Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
Center for Infection Research, University Würzburg, Würzburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH